Pawel Baranczewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pawel Baranczewski has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Annika Lindqvist
Department of Pharmacy, SciLifeLab Drug Discovery and Development Platform, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden
2 shared publications - Maria Backlund
Department of Pharmacy, Uppsala Drug Optimization and Pharmaceutical Profiling, Uppsala University
2 shared publications Solveiga Grinberga
Latvian Institute of Organic Synthesis
2 shared publications- Alain Fournet
IRD, Laboratoire de Pharmacognosie, Faculté de Pharmacie, Université Paris-Orsay, 92290 Châtenay-Malabry, France
1 shared publication - Alejandro Díaz Holguín
Uppsala University
1 shared publication Ali F. Aboklaish
Department of Medical Microbiology, Institute of infection & Immunity, Cardiff University, Cardiff, UK
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1628-1631
Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum
- 16 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1628-1631
Open AccessDabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum
- Open Access
- 15 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
Setting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements
Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding. It is essential that the information from lactation studies is trustworthy and fulfils regulatory standards and requirements for the results to be fit for label. In this paper we describe the premises and conditions for mother–infant pair studies and biobanking for research of collected samples as laid down in regulatory requirements. The studies on metformin are still ongoing. At the time of the study (June 2025), 18 participants had been included in the metformin study and 20 in the prednisolone study. Evidence for the use of medicines in association with breastfeeding is urgently needed, both for already approved and used drugs, and for the development of new drugs. Based on our experiences within the IMI‐ConcePTION project, we have described the premises for mother–infant pair studies to be adhered to.
- 15 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessSetting up mother–infant pair lactation studies with biobanking for research according to regulatory requirements
Within the ConcePTION project we set out to design two mother–infant pair studies collecting breast milk and plasma from the mother and plasma from the infant (for metformin and prednisolone) in order to demonstrate the premises and conditions for investigating potential drug transfer in association with breastfeeding. It is essential that the information from lactation studies is trustworthy and fulfils regulatory standards and requirements for the results to be fit for label. In this paper we describe the premises and conditions for mother–infant pair studies and biobanking for research of collected samples as laid down in regulatory requirements. The studies on metformin are still ongoing. At the time of the study (June 2025), 18 participants had been included in the metformin study and 20 in the prednisolone study. Evidence for the use of medicines in association with breastfeeding is urgently needed, both for already approved and used drugs, and for the development of new drugs. Based on our experiences within the IMI‐ConcePTION project, we have described the premises for mother–infant pair studies to be adhered to.
- Top Cited PapersOpen Access
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadn1524
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine–associated receptor 1 (TAAR1), a G protein–coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 μM. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadn1524
Top Cited PapersOpen AccessAlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine–associated receptor 1 (TAAR1), a G protein–coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 μM. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.
- Open Access
- 5 April 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (15)
Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria
Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and there is no analogous pathway in humans. Based on a series of phenotypic screens, we identified a hit targeting this pathway that had activity on efflux-defective strains of Escherichia coli . We recognized common structural elements between this hit and a previously published inhibitor, also with activity against efflux-deficient bacteria. With the help of X-ray structures, this information was used to design inhibitors with activity on efflux-proficient, wild-type strains. Optimization of properties such as solubility, metabolic stability and serum protein binding resulted in compounds having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae . Other favorable properties of the series include a lack of pre-existing resistance in clinical isolates, and no loss of activity against strains expressing extended-spectrum-β-lactamase, metallo-β-lactamase, or carbapenemase-resistance genes. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.
- 5 April 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (15)
Open AccessAntibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria
Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and there is no analogous pathway in humans. Based on a series of phenotypic screens, we identified a hit targeting this pathway that had activity on efflux-defective strains of Escherichia coli . We recognized common structural elements between this hit and a previously published inhibitor, also with activity against efflux-deficient bacteria. With the help of X-ray structures, this information was used to design inhibitors with activity on efflux-proficient, wild-type strains. Optimization of properties such as solubility, metabolic stability and serum protein binding resulted in compounds having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae . Other favorable properties of the series include a lack of pre-existing resistance in clinical isolates, and no loss of activity against strains expressing extended-spectrum-β-lactamase, metallo-β-lactamase, or carbapenemase-resistance genes. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.
- Open Access
- 13 November 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 134 (1) , 153-164
Transfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding: A human lactation study from the ConcePTION project
Data on drug transfer into human breast milk are sparse. This study aimed to quantify concentrations of cetirizine and levocetirizine in breast milk and to estimate drug exposure to infants. Breastfeeding women at least 8 weeks postpartum and using cetirizine or its pure (R)‐enantiomer levocetirizine were eligible to participate. Breast milk samples were collected at six predefined times during a dose interval (0, 2, 4, 8, 12 and 24 h after drug intake) at steady state. Infant drug exposure was estimated by calculating the absolute infant dose (AID) and the weight‐adjusted relative infant dose (RID). In total, 32 women were eligible for final inclusion, 31 women using cetirizine and one woman using levocetirizine. Means of the individual maximum and average cetirizine milk concentrations were 41.0 and 16.8 μg/L, respectively. Maximum concentrations occurred on average 2.4 h after intake, and the mean half‐life in milk was 7.0 h. Estimated AID and RID for cetirizine in a day were 2.5 μg/kg and 1.9%, respectively. The corresponding values for levocetirizine were 1.1 μg/kg and 1.9%. No severe adverse events were reported. Our findings demonstrate that the transfer of cetirizine and levocetirizine into breast milk is low and compatible with breastfeeding.
- 13 November 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 134 (1) , 153-164
Open AccessTransfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding: A human lactation study from the ConcePTION project
Data on drug transfer into human breast milk are sparse. This study aimed to quantify concentrations of cetirizine and levocetirizine in breast milk and to estimate drug exposure to infants. Breastfeeding women at least 8 weeks postpartum and using cetirizine or its pure (R)‐enantiomer levocetirizine were eligible to participate. Breast milk samples were collected at six predefined times during a dose interval (0, 2, 4, 8, 12 and 24 h after drug intake) at steady state. Infant drug exposure was estimated by calculating the absolute infant dose (AID) and the weight‐adjusted relative infant dose (RID). In total, 32 women were eligible for final inclusion, 31 women using cetirizine and one woman using levocetirizine. Means of the individual maximum and average cetirizine milk concentrations were 41.0 and 16.8 μg/L, respectively. Maximum concentrations occurred on average 2.4 h after intake, and the mean half‐life in milk was 7.0 h. Estimated AID and RID for cetirizine in a day were 2.5 μg/kg and 1.9%, respectively. The corresponding values for levocetirizine were 1.1 μg/kg and 1.9%. No severe adverse events were reported. Our findings demonstrate that the transfer of cetirizine and levocetirizine into breast milk is low and compatible with breastfeeding.
- 13 December 2021
- Published by Springer Nature in Nature Chemistry
- Vol. 14 (1) , 15-24
Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors
Carbapenems are vital antibiotics, but their efficacy is increasingly compromised by metallo-β-lactamases (MBLs). Here we report the discovery and optimization of potent broad-spectrum MBL inhibitors. A high-throughput screen for NDM-1 inhibitors identified indole-2-carboxylates (InCs) as potential β-lactamase stable β-lactam mimics. Subsequent structure–activity relationship studies revealed InCs as a new class of potent MBL inhibitor, active against all MBL classes of major clinical relevance. Crystallographic studies revealed a binding mode of the InCs to MBLs that, in some regards, mimics that predicted for intact carbapenems, including with respect to maintenance of the Zn(II)-bound hydroxyl, and in other regards mimics binding observed in MBL–carbapenem product complexes. InCs restore carbapenem activity against multiple drug-resistant Gram-negative bacteria and have a low frequency of resistance. InCs also have a good in vivo safety profile, and when combined with meropenem show a strong in vivo efficacy in peritonitis and thigh mouse infection models.
- 13 December 2021
- Published by Springer Nature in Nature Chemistry
- Vol. 14 (1) , 15-24
Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors
Carbapenems are vital antibiotics, but their efficacy is increasingly compromised by metallo-β-lactamases (MBLs). Here we report the discovery and optimization of potent broad-spectrum MBL inhibitors. A high-throughput screen for NDM-1 inhibitors identified indole-2-carboxylates (InCs) as potential β-lactamase stable β-lactam mimics. Subsequent structure–activity relationship studies revealed InCs as a new class of potent MBL inhibitor, active against all MBL classes of major clinical relevance. Crystallographic studies revealed a binding mode of the InCs to MBLs that, in some regards, mimics that predicted for intact carbapenems, including with respect to maintenance of the Zn(II)-bound hydroxyl, and in other regards mimics binding observed in MBL–carbapenem product complexes. InCs restore carbapenem activity against multiple drug-resistant Gram-negative bacteria and have a low frequency of resistance. InCs also have a good in vivo safety profile, and when combined with meropenem show a strong in vivo efficacy in peritonitis and thigh mouse infection models.
- 1 June 2007
- Published by Elsevier in Toxicology
- Vol. 235 (1-2) , 27-38
Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS
- 1 June 2007
- Published by Elsevier in Toxicology
- Vol. 235 (1-2) , 27-38
Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS
- 1 January 1998
- Published by Springer Nature in Chromosome Research
- Vol. 6 (1) , 59-63
The acetylation patterns of histones H3 and H4 along Vicia faba chromosomes are different
The acetylation pattern of H3 was studied on field bean chromosomes by means of indirect immunofluorescence using polyclonal antibodies recognizing H3 isoforms acetylated at lysine positions 9/18, 14...
- 1 January 1998
- Published by Springer Nature in Chromosome Research
- Vol. 6 (1) , 59-63
The acetylation patterns of histones H3 and H4 along Vicia faba chromosomes are different
The acetylation pattern of H3 was studied on field bean chromosomes by means of indirect immunofluorescence using polyclonal antibodies recognizing H3 isoforms acetylated at lysine positions 9/18, 14...